Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2001 Jun;45(6):1908-10.
doi: 10.1128/AAC.45.6.1908-1910.2001.

In vitro activities of moxifloxacin and other fluoroquinolones against Mycoplasma pneumoniae

K Hamamoto  1 , T Shimizu, N Fujimoto, Y Zhang, S Arai
Affiliations

In vitro activities of moxifloxacin and other fluoroquinolones against Mycoplasma pneumoniae

K Hamamoto et al. Antimicrob Agents Chemother. 2001 Jun.

Abstract

A total of 105 isolates of Mycoplasma pneumoniae were evaluated for susceptibility to moxifloxacin, sparfloxacin, levofloxacin, and ciprofloxacin. Moxifloxacin, a newly synthesized compound, showed the greatest activity. The MICs and MBCs at which 50 and 90% of isolates were affected were 0.15 (MIC(50) and MBC(50)) and 0.3 microg/ml (MIC(90) and MBC(90)) respectively. The results indicate that moxifloxacin might be promising an antimycoplasmal agent.

PubMed Disclaimer

Figures

FIG. 1
FIG. 1
Susceptibilies of 105 strains of M. pneumoniae to moxifloxacin and other fluoroquinolones. (a) MICs. (b) MBCs. Symbols: ●, moxifloxacin; ■, SPFX; ▴, LVFX; ▾, CPFX. The numbers of strains are indicated at the bottom.
See this image and copyright information in PMC

References

    1. Angela B B, Kari C K, Gary V D. In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Antimicrob Agents Chemother. 1997;41:1594–1597. - PMC - PubMed
    1. Arai S, Gohara Y, Akashi A, Kuwano K, Nishimoto M, Yano T, Oizumi K, Takeda K, Yamaguchi T. Effects of new quinolones on Mycoplasma pneumoniae-infected hamasters. Antimicrob Agents Chemother. 1993;37:287–292. - PMC - PubMed
    1. Boswell F J, Andrews J M, Wise R. Pharmacodynamic properties of BAY 12-8039 on gram-positive and gram-negative organisms as demonstrated by studies of time-kill kinetics and post antibiotic effect. Antimicrob Agents Chemother. 1997;41:1377–1379. - PMC - PubMed
    1. Cassell G H, Waites K B, Pate M S, Canupp K C, Duffy L B. Comparative susceptibility of Mycoplasma pneumoniae to erythromycin, ciprofloxacin, and lomefloxacin. Diagn Microbiol Infect Dis. 1989;12:433–435. - PubMed
    1. Gohara Y, Arai S, Akashi A, Kuwano K, Tseng C, Matsubara S, Matumoto M, Furudera T. In vitro and in vivo activities of Q-35, a new fluoroquinolone, against Mycoplasma pneumoniae. Antimicrob Agents Chemother. 1993;37:1826–1830. - PMC - PubMed

LinkOut - more resources